Dana T. Aftab, Ph.D.
Equibles does not estimate personal net worth.
Get an email with a short summary when Exelixis, Inc. publishes a filing, an earnings call transcript or a press release.
Get EXEL alertsAbout Dana T. Aftab, Ph.D.
Exelixis, Inc. reported in an 8-K filed August 29, 2025 that Dana T. Aftab, Ph.D. was appointed Executive Vice President, Research and Development, effective August 29, 2025. Exelixis, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Exelixis, Inc. includes Michael M. Morrissey (CEO and Board Member), Michael Morrissey (CEO and Board Member), Christopher Senner (CFO) and 7 others.
“On August 29, 2025, the Board of Directors (the "Board") of Exelixis, Inc. (the "Company") appointed Dana T. Aftab, Ph.D., the Company's current Executive Vice President, Discovery and Translational Research and Chief Scientific Officer as Executive Vice President, Research and Development.”
Affiliation history
-
Exelixis, Inc. (EXEL)
SEC 8-K
Current2025-08-29–present
Company network
Leadership on record at Exelixis, Inc.
- Michael M. Morrissey CEO, Board Member
- Michael Morrissey CEO, Board Member
- Christopher Senner CFO
- Brenda Hefti, J.D., Ph.D. General Counsel
- Brenda J. Hefti General Counsel
- Alan M. Garber, M.D., Ph.D. Board Member
- Carl B. Feldbaum, Esq. Board Member
- Charles Cohen, Ph.D. Board Member
- David E. Johnson Board Member
- George Poste Board Member